| # | Drug | Count |
|---|---|---|
| 0 | ADAPALENE | 972 |
| 1 | ETANERCEPT | 708 |
| 2 | ADALIMUMAB | 691 |
| 3 | METHOTREXATE SODIUM | 634 |
| 4 | METHOTREXATE | 566 |
| 5 | PREDNISONE | 439 |
| 6 | ACETAMINOPHEN | 420 |
| 7 | ERGOCALCIFEROL | 377 |
| 8 | DUPILUMAB | 368 |
| 9 | INFLIXIMAB | 339 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ZINGIBER OFFICINALE | 36 | 0.4138 |
| 1 | CHLORHEXIDINE GLUCONATE 2% | 13 | 0.1585 |
| 2 | PANITUMUMAB | 295 | 0.0183 |
| 3 | IMIQUIMOD | 39 | 0.0167 |
| 4 | INFLIXIMAB-DYYB | 47 | 0.0136 |
| 5 | ERGOCALCIFEROL | 377 | 0.0127 |
| 6 | MECHLORETHAMINE HYDROCHLORIDE | 26 | 0.0116 |
| 7 | GOLIMUMAB | 140 | 0.0111 |
| 8 | CLINDAMYCIN PHOSPHATE | 60 | 0.0109 |
| 9 | GOLD | 57 | 0.0098 |
| # | Drug class | Count |
|---|---|---|
| 0 | Tumor Necrosis Factor Blocker [EPC] | 1137 |
| 1 | Corticosteroid [EPC] | 1078 |
| 2 | Retinoid [EPC] | 1020 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 965 |
| 4 | Folate Analog Metabolic Inhibitor [EPC] | 600 |
| 5 | Epidermal Growth Factor Receptor Antagonist [EPC] | 547 |
| 6 | Platinum-based Drug [EPC] | 490 |
| 7 | Kinase Inhibitor [EPC] | 448 |
| 8 | Nucleoside Metabolic Inhibitor [EPC] | 429 |
| 9 | CD20-directed Cytolytic Antibody [EPC] | 382 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 24 | 0.0349 |
| 1 | Provitamin D2 Compound [EPC] | 377 | 0.0127 |
| 2 | Epidermal Growth Factor Receptor Antagonist [EPC] | 547 | 0.0116 |
| 3 | Endoglycosidase [EPC] | 17 | 0.0092 |
| 4 | Human Immunoglobulin G [EPC] | 134 | 0.0064 |
| 5 | Interleukin-17A Antagonist [EPC] | 229 | 0.0061 |
| 6 | CD38-directed Cytolytic Antibody [EPC] | 31 | 0.0053 |
| 7 | Mucocutaneous Epithelial Cell Growth Factor [EPC] | 2 | 0.0051 |
| 8 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 40 | 0.0046 |
| 9 | Sclerosing Agent [EPC] | 2 | 0.0044 |